Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 468

Results For "CE"

9359 News Found

Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
News | November 16, 2025

Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY

EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025


Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr
News | November 16, 2025

Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr

Total income for the period stood at Rs. 7101.28 crore


Abbott unveils new diabetes care formula amid rising global diabetes crisis
News | November 16, 2025

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health


Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities
News | November 15, 2025

Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities

The observations are procedural in nature and will be responded to within the stipulated time


Merck to acquire Cidara Therapeutics for $9.2 billion
Biotech | November 15, 2025

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent


Lupin achieves S&P Global ESG score of 91
Sustainability | November 14, 2025

Lupin achieves S&P Global ESG score of 91

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth


Novartis opens radioligand therapy facility in Carlsbad, US
News | November 14, 2025

Novartis opens radioligand therapy facility in Carlsbad, US

Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio


Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Clinical Trials | November 14, 2025

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia